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tive of the model was to assess the change of disease progression due to higher 
percentage of treated patients with iv iron and subsequently the impact on the 
health care costs. Disease progression was modelled by using a sequential Markov 
model with monthly transitions of NYHA health states of the cohort. The model 
takes into account direct costs (NYHA, hospital, outpatient and iron therapy) from 
2014 and data from a systematic literature review (RCT, cohort studies and clinical 
guidelines). Results: The result of the BIA shows that an increased use of iv iron 
therapy (based on a iv iron treatment scenario- treated patients +20% and iv iron 
treated patients +10%) in Austria would lead to a positive budget impact. By treating 
ID with FCM saving effects are achieved through reduced cost in the CHF manage-
ment (NYHA class shift) and reduced hospitalizations. The overall saving effect was 
calculated as € 225,115 in 2014 to € 684,443 in the 3rd year. ConClusions: Iv iron 
therapy with FCM in iron deficient CHF patients can be associated with substantial 
cost savings based on reduced hospitalisations and improved CHF functional class 
(NYHA).
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objeCtives: Assessing the benefit of enoxaparine on healthcare budget for the 
prophylaxis of the venous thromboembolism disease (VTE) and the treatment of 
deep vein thrombosis (DVT) with and without pulmonary embolism (EP) in Spain 
and its Autonomous Communities (ACs). Methods: Prophylaxis patients were clas-
sified as moderate or high-risk according to the surgery type. The budget impact was 
estimated by comparing the cost in a scenario where 100% of the market is covered 
with enoxaparine from a scenario with only bemiparine. An additional analysis was 
performed considering the current treatment setting with all heparins available 
in the market versus a projected scenario where all patients receive enoxaparine. 
Cost estimation was based on real sales per product and pack over a year (March 
2014 to February 2015) obtained from IMS Health database (Dataview), and on the 
retail price plus the value-added tax in 2015, discounting the deductions according 
to Royal Decrees. Results: In the scenario comparing enoxaparine to bemiparine, 
the administration of enoxaparine for VTE prophylaxis would lead to a cost saving 
for the national health system of 10.138.123€ for high-risk patients and 744.684€ 
for moderate risk patients, depending on the AC savings range from 22.524€ to 
1.952.898€ and from 2.314€ to 162.328€ in patients with high and moderate risk, 
respectively. In the treatment of DVT at national level the average savings come to 
8.125.273€ , and at regional level these vary between 21.969€ and 1.671.395€ . Savings 
obtained when comparing a scenario with only enoxaparine versus the current 
setting with all heparins come to 3.368.555€ and 9.813.120€ for prophylaxis of VTE 
and treatment of DVT, respectively, at national level. ConClusions: Broader use of 
enoxaparine for the prophylaxis of VTE and treatment of DVT with and without PE in 
Spain and its ACs would lead to an economic benefit for the Spanish health system.
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objeCtives: Venous thromboembolism (VTE) is the third most common cause of 
death from cardiovascular disease after acute MI and stroke. Initial treatment of 
VTE using heparin or LMWH has been recommended by different international 
guidelines. The aim of this study was to analyze the economic impact that could 
represent the use of bemiparin compared with the conventional treatment in 
Spain. Methods: An interactive Excel model for 3 years was developed using 
data obtained through a published literature review, including treatment costs and 
complications costs, for the Spanish National Health System. Public prices + VAT 
of bemiparin and enoxaparin were used. We consider a conservative co-payment 
of 40% for all patients. Patients were treated with LMWH for 7 days. Percentages 
and costs of complications were obtain from the literature. Three scenarios were 
designed: In the first scenario, patients were treated with bemiparin or enoxaparin 
using the current marked share, in the second 100% of patients were treated with 
bemiparin and, in the third scenario, 100% of patients were treated with enoxa-
parin. Results: The budget impact (per year, same during the 3 years) of the use 
of only bemiparin resulted in a 13% of cost savings related to the current scenario 
and in a 17% of cost savings compared with only enoxaparin. Enoxaparin compared 
with the current scenario resulted in a 4% of incremental costs. Bemiparin repre-
sents savings of around € 700,000 per year compared with current treatment and 
around € 900,000 per year when it is used in a 100% of patients instead of enoxa-
parin. ConClusions: The budget impact analysis may be important when decid-
ing which LWMH to use for the treatment of VTE. This analysis provides evidence 
reinforcing the use of bemiparin as the LMWH of choice, because its use resulted in 
a budget impact reduction for the Spanish National Health System.
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intRoduCtion: Statin therapy has proved effective in reducing cardiovascular 
morbidity and mortality. However, the cost of a defined daily dose (DDD) differs 
from a statin to another, being generally atorvastatin and simvastatin the best 
choice under the criteria of cost effectiveness. objeCtives: To assess the conse-
quences in terms of outpatient pharmaceutical expenditure and DDD prescribed, 
that accounted due to the introduction of “prescription algorithms” into the elec-
tronic prescribing tool for physicians. Check whether the prescription of statins has 
been moved towards cost effective alternatives. Methods: Cross-sectional study 
outpatient management were obtained by micro-costing. Costs were expressed in 
2015 prices and exchange rate was $1.00USD= 3.00BRL. Results: It was estimated 
60,279 patients with VTE in the entire private health system, which by switching to 
rivaroxaban, would result in overall $38.4 million savings. From the single health plan 
perspective, an average of 540, 56 and 9 patients with VTE are expected for the three 
profiles and would result in savings of $343.0, $35.8 and $5.6 thousands, respectively 
in big, medium and small size plans. Cost savings are mainly associated with shorter 
length of stay with rivaroxaban. Robustness of the model was tested in deterministic 
univariate sensitivity analysis in which results remained cost saving. ConClusions: 
Rivaroxaban has potential to yield savings for VTE treatment under Brazilian private 
system perspective.
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objeCtives: Venous thromboembolism (VTE), including deep vein thrombosis 
(DVT) and pulmonary embolism (PE) represents the third most common cardio-
vascular pathology after acute coronary syndrome and stroke. Rivaroxaban, a novel 
oral simplified therapy approved for treatment of DVT and PE leads to reduction in 
thromboembolic and haemorrhagic events and does not need laboratory monitor-
ing. This study aims to evaluate the economic impact of the use of rivaroxaban for 
preventing DVT and PE in Italy. Methods: The present analysis estimates clinical 
outcomes and economic consequences of the substitution of rivaroxaban versus 
standard therapy [(low molecular weight heparin (LMWH) + vitamin K antagonists 
(VKA)] for the treatment of VTE. In the analysis we considered a progressive replace-
ment of LMWH/VKA with rivaroxaban (22%, 25%, and 27% in DVT and 12%, 16%, and 
20% in PE) over a three years time horizon. Clinical outcomes with the two alterna-
tive treatments available were estimated using data from the EINSTEIN studies, 
which directly compare rivaroxaban with LMWH/VKA. Direct healthcare costs have 
been estimated in the perspective of Italian National Health Service (INHS) (drugs, 
hospitalizations, visits and laboratory monitoring). Results: The replacement 
of LMWH/VKA with rivaroxaban in DVT and PE is associated with a reduction in 
events (recurrent symptomatic thromboembolism, major bleeding, vascular events 
and mortality). This reduction, together with the absence of laboratory monitor-
ing costs for patients treated with rivaroxaban leads to an expenditure saving for 
the INHS in the first three years of about € 8.4 million in DVT and € 3.2 million 
in PE. ConClusions: The simplified therapy with rivaroxaban, as confirmed by 
the clinical trials, may provide significant clinical advantages in terms of avoided 
events and related costs. Moreover, without the need for laboratory monitoring, the 
increase in pharmacological expenditure is completely compensated leading overall 
to significant cost savings to the INHS.
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objeCtives: The objective of this study was to perform a Budget Impact Analysis 
(BIA) assessing the introduction of Tripliam for the treatment of hypertension into 
the Italian market. Tripliam is the first and only available single-tablet triple com-
bination antihypertensive therapy containing perindopril, amlodipine and inda-
pamide, in line with current evidence-based recommendations for the treatment 
and management of hypertension. Methods: The BIA compared two different 
scenarios: Scenario 1 without a triple fixed combination therapy vs. Scenario 2 with 
the introduction of Tripliam. Population data were obtained from a Local Project 
Database by Cegedim. The time horizon considered was 3 years from the introduc-
tion of Tripliam. Total number of patients in each of the 3 years was the same for the 
two Scenarios, because the model allows only the switch of patients from the dual 
or triple combinations to the fixed dose treatment with Tripliam. The perspective 
of the Italian National Healthcare Service was considered. Results: The study 
showed that the introduction of Tripliam leads to a reduction in the quantity of pills 
taken by patients (7.014.644, 8.743.882 and 10.127.208 in Scenario 1 and 6.469.258, 
7.762.951 and 8.657.031 in Scenario 2, respectively in year 1, 2 and 3). With a cost of 
11,26 € /month, the introduction of Tripliam generates a very limited incremental 
costs in year 1 and 2 (respectively 2.977 € and 501 € ) and a saving in the third year 
(3.478 € ) over the total expenditure of 45.7, 51.9 and 56.7 respectively in year 1, 2 
and 3 in the two scenarios. ConClusions: The present study indicates that the 
introduction of Tripliam does not imply additional treatment costs, but improves 
the adherence to the therapy, thanks to the reduction in the number of pills taken 
by patients. Better adherence is also linked to a reduction in the number of hospi-
talizations and related costs.
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objeCtives: Iron deficiency (ID) is highly prevalent in chronic heart failure (CHF) 
patients and imposes a significant disease burden for CHF patients with enormous 
impact on their outcome. CHF with ID is a major reason for hospitalization and 
represents important costs for the national health care budget in Austria. Yet, only 
a small percentage of CHF patients with ID are diagnosed. Thus, the objective of 
this analysis is the evaluation of the cost saving potential through an increased 
use of intravenous iron therapy with ferric carboxymaltose (FCM) based on clinical 
trial evidence. Methods: A budget impact analysis (BIA) with a four-year’s time 
horizon was developed from the health insurance perspective. The main objec-
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objeCtives: To estimate hospital costs for cardiovascular (CV) events and revas-
cularisation procedure associated with inpatient care analysing data from 14 
acute care Spanish hospitals (RECH network), and to compare these costs with 
national tariffs for the corresponding diagnosis-related groups (DRGs) for similar 
events. Methods: A retrospective study (period: 2009-2013) collecting data from 
discharge records (~1,050,000) from adult patients was performed. Mean costs and 
length of stay per patient were collected for non-fatal events according primary 
diagnosis (CIE9-MC) including myocardial infarction (MI), unstable angina, conges-
tive heart failure (CHF) with hospitalization, stroke, revascularisation procedures 
and CV death. Average costs per patient for non-fatal CV events, revascularisa-
tion procedures and CV death were estimated according per-patient cost informa-
tion from the RECH database, that included both AP-DRG and APR-DRG groupers 
which are used for alternative cost comparisons. Subsequently, observed costs per 
DRG were compared with national DRG tariffs. All costs were expressed in € for 
the year 2014. Results: Mean costs based on patient-level data from the RECH 
network for non-fatal acute MI, unstable angina, CHF with hospitalisation, stroke 
and revascularisation procedures were € 8,669, € 3,162, € 3,353, € 4,644 and € 10,159 
respectively. Average length of stay for non-fatal events ranged between 5.3 and 
10.2 hospitalisation days and between 6.4 and 19.5 for revascularisation proce-
dures. The comparison of costs from the RECH network with national tariffs for 
AP-DRGs, showed differences of € 57 for revascularisation procedures, € 298 for CHF 
with hospitalisation, € 1,096 for unstable angina, € 1,316 for stroke, € 3,794 for CV 
death and € 4,249 for acute MI. ConClusions: Average per-patient costs based 
on discharge records from the RECH network for CV events and revascularisation 
procedures were higher than the national tariffs for AP-DRGs of similar events and 
procedures. These differences may result in important economic consequences for 
the Spanish health system.
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objeCtives: To understand the hospitalization expenses and the cost-sharing situ-
ation among Chinese stroke patients covered by Urban Employee Basic Medical 
Insurance (UEBMI). Methods: The data are derived from China Health Insurance 
Research Association’s (CHIRA) Survey (2012). The survey adopts the systematic 
sampling method to draw samples from the inpatients with UEBMI of the previous 
year and gets details about their disease diagnosis, medical service utilization and 
expenses. The sampling rate varies with different regions with an average rate of 
2%~10%. SPSS17.0 is used to conduct the statistical analysis. Results: A total of 
22,765 stroke patients were obtained from the sampling. The proportion of male 
stroke patients (59%) was obviously higher than female patients (41%). As for age, 
stroke patients aged 70~79 accounted for the highest ratio (32%), followed by 60~69 
(27%) and 50~59 (19%). The average LOS of stroke patients was 16.2 days, which 
was longer in the tier-3 hospitals (17.4 days) than in the tier-2 ones (15.3 days). The 
average hospitalization expenses were 8,598 yuan, the average drug expenses were 
5,049 yuan, accounting for about 59% of the total hospitalization expenses. Average 
costs of the tier-3 hospitals were higher than other hospitals, with the average hos-
pitalization expenses being 13,381 yuan and the average drug expenses being 7,318 
yuan (occupying about 55% of the hospitalization expenses). The UEBMI payment 
accounted for about 69% of the total hospitalization expenses and about 79% of the 
drug cost. Patients’ co-payment proportion was higher in tier-3 hospitals than other 
ones. ConClusions: Chinese stroke patients are mostly over 50 years old, with 
more male patients than female patients. The average hospitalization expenses 
are 8,598 yuan and payer’s payment proportion is lower than 70%. Expenses of the 
tier-3 hospitals are apparently higher than other hospitals. Medicine charges take 
up more than half of the hospitalization expenses.
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objeCtives: Comparative evaluation of the cost effectiveness of treatment of 
patients with acute coronary syndrome without ST segment elevation (ACS) effi-
ciency using two therapy schemes in Ukraine. Methods: “The cost-efficiency” 
method was used to carrying out the study. Analysis was based on the results of 
opened international multicenter randomized trial of efficiency of tiazotic acid 
morpholinium salt in ACS patients. The clinical trial involved 100 patients rand-
omized into main and control groups (each group contained 50 patients). Standard 
therapy (narcotic analgesics, seduction drugs, nitrates, β -blockers, anticoagulants, 
antithrombotic drugs, calcium channel blockers, ACEs, sartans and statins) and 
injections of tiazotic acid morpholinium salt were administrated in the main group; 
only standard therapy was administrated in the control group. Treatment of patients 
was carried out during 14 days. For determining the cost of a course therapy for 
a patient with craniocerebral injury only the direct costs in the studied regimens 
were taken into account. Drugs prices were taken from Morion’s information system 
(May, 2015). As an indicator of the effectiveness after treatment were considered the 
following: 5 % increase in ejection fraction, 10 % decreasing in myocardial ischemia 
duration (based on Holter ECG monitoring), 10 % decrease in quantity of ventricu-
lar arrhythmia episodes (based on ECG Holter monitoring). Results: The treat-
ment efficiency in main group patients was 84 % and 54 % in controls. Treatment 
during 2012, 2013 and 2014. Two health regions of Spain (Comunitat Valenciana with 
4.949.219 inhabitants and Extremadurawith 1.093.587. Total population: 6,042,806) 
where compared. In order to make it comparable, DDDs where measured as num-
bers of DDDs/1000 inhabitants/day (DHDs). Results: Atorvastatin and simvastatin 
are the most prescribed statins in both regions. However in Extremadura, the pro-
portion of DHD of these two chemical substances over the total amount of statins 
has decreased from 70.13% in 2012 to 68.00% in 2014. By contrast, in Comunitat 
Valenciana the proportion has increased from 73.45% in 2012 to 82.40% in 2014. In 
both regions the number of DHD of statins increases (in Extremadura from 106.75 
DHD in 2012 to 120.14 DHD in 2014; in Comunitat Valenciana from 98.08 DHD in 
2012 to 104.15 DHD in 2014). However, in Comunitat Valenciana the increase in 
consumption has not resulted in increased drug spending but in a drop of 7.41%. 
By contrast, Extremadura’s pharmaceutical expenditure of statins has increased 
a 17.62%. ConClusions: In the region that did not introduced the algorithm for 
statins into the electronic prescribing tool, less cost effective statins are gaining 
market share. In the region which introduced the prescription algorithm, although 
statin use increases, its pharmaceutical expenditure decreases, resulting in savings 
that can be spent elsewhere medication.
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objeCtives: The Prescription e-Protocols for Medicines (PePM), which devel-
oped under the coordination of the Athens Medical Society (AMS), are to be used 
by all physicians as an aid in prescription and to set out a framework of “good 
medical practice”, based on the up-to-day clinical evidence. To make the use of 
prescription protocols efficient, the main objective was to transform the proto-
col’s information into machine processable format, integrate with the national 
e-prescription system and measure the cost impact. Methods: AMS has already 
developed prescription e-protocols for seven therapeutic categories (20 proto-
cols). The representation model of PePM includes five levels of information: gen-
eral information, treatment steps and sub-conditions according the use of risk 
assessment algorithms, treatment at active substance level and at product level. 
The process of prescribing according to PePM, includes: select protocol accord-
ing to ICD10 diagnoses, insert input parameters, select medication and finalize 
prescription. Their cost impact was measured by comparing the periods of using 
the protocols with the relevant period not using them on the Greek National 
ePrescription system. Results: Using the example of the dyslipidemia proto-
col and the stratification of the population according to heart score algorithm, 
comparing statins use, between two periods (09-11/2013 vs 09-11/2014) had an 
overall reduction of the cost by 15.85%. Reduction of the second step statins’ 
cost: atorvastatin -17.16%, rosuvastatin -3.93%, ezetimibe -29.83%, ezetimibe/
simvastatin -12.38%. ConClusions: The recent economic crisis and subse-
quent public expenditure cuts have slowed the rate of heath expenditure growth. 
Pharmaceutical expenditure has even decreased as it has been identified as one 
of the main areas of public spending cuts. Our proposal concerns that suitable 
prescribing guidelines with the integration on the ePrescription system ensures 
patient access to quality health service and containing costs according to real 
health needs and in alignment with evidence-based medicine principles.
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objeCtives: To estimate monthly medical costs of controlled and inadequately-
controlled non-valvular atrial fibrillation (NVAF) patients treated with Vitamin K 
antagonists (VKA). Methods: Retrospective cohort study of NVAF patients newly 
initiating VKA between January 2009 and December 2014 using a database from 
a healthcare provider from Badalona (Spain) (120,000 inhabitants). We followed 
patients from first VKA treatment until study end, leaving database, VKA discontin-
uation, or death; calculated proportion of patients with adequate anticoagulation 
(time in therapeutic range (TTR) ≥ 60% using target international normalized ratio 
(INR) 2-3) over 12 months post-initiation; and estimated monthly mean healthcare 
costs linked to NVAF for controlled and inadequately-controlled patients, adopting 
a payer perspective. Results: The study included 1,144 patients (median(IQR) 
follow-up 28.8 (14.2–43.1) months) with 67.1% well-controlled patients over 0-12 
month period. At baseline, for controlled and inadequately-controlled patients 
respectively, mean(SD) age was 74.3(10.3) and 74.3(10.7) years and 48.2% and 
54.3% were female. Mean Charlson index was 0.9(1.4) and 1.1(1.4), (p:0.025), and 
CHA2DS2-VASc scores were 2.7(1.6) and 2.9(1.6) (p:0.038) for controlled and inad-
equately-controlled patients, respectively. Mean(SD) monthly medical costs were 
€ 80.3(174.8) and € 143.6(656.6) respectively, being 1.8-fold higher for inadequately-
controlled patients (p:0.013). The largest cost components were general practi-
tioner visits, hospitalizations, and specialist visits. INR testing was also more 
costly in inadequately-controlled patients (mean monthly INR cost(SD) € 2.3(1.1) 
versus € 2.7(1. 9) p:< 0.001 for controlled and inadequately-controlled patients 
respectively) and accounted for 1.9% and 2.9% of costs, respectively. Other time 
periods assessed gave qualitatively similar results. ConClusions: In this study, 
1/3 of NVAF patients treated with VKAs were inadequately controlled. These 
patients had a higher baseline stroke risk and comorbidity index and generated 
higher direct medical costs associated with NVAF compared to controlled patients. 
In this context, future research could address the medical costs associated with 
novel anticoagulants in NVAF patients.
